Theravance Biopharma Inc (TBPH)
8.48
+0.05
(+0.59%)
USD |
NASDAQ |
Jun 18, 16:00
8.49
+0.01
(+0.12%)
After-Hours: 20:00
Theravance Biopharma Free Cash Flow: -18.44M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -18.44M |
| December 31, 2023 | -29.48M |
| September 30, 2023 | -152.28M |
| June 30, 2023 | -171.85M |
| March 31, 2023 | -173.40M |
| December 31, 2022 | -187.56M |
| September 30, 2022 | -106.12M |
| June 30, 2022 | -130.52M |
| March 31, 2022 | -165.95M |
| December 31, 2021 | -211.26M |
| September 30, 2021 | -234.56M |
| June 30, 2021 | -267.15M |
| March 31, 2021 | -272.60M |
| December 31, 2020 | -257.02M |
| September 30, 2020 | -256.50M |
| June 30, 2020 | -222.12M |
| March 31, 2020 | -215.02M |
| December 31, 2019 | -241.37M |
| September 30, 2019 | -229.40M |
| June 30, 2019 | -235.55M |
| March 31, 2019 | -249.57M |
| Date | Value |
|---|---|
| December 31, 2018 | -120.11M |
| September 30, 2018 | -110.89M |
| June 30, 2018 | -123.16M |
| March 31, 2018 | -105.79M |
| December 31, 2017 | -203.46M |
| September 30, 2017 | -187.51M |
| June 30, 2017 | -137.23M |
| March 31, 2017 | -124.74M |
| December 31, 2016 | -101.12M |
| September 30, 2016 | -106.96M |
| June 30, 2016 | -126.78M |
| March 31, 2016 | -141.33M |
| December 31, 2015 | -171.50M |
| September 30, 2015 | -180.46M |
| June 30, 2015 | -184.64M |
| March 31, 2015 | -189.01M |
| December 31, 2014 | -178.26M |
| September 30, 2014 | -171.21M |
| June 30, 2014 | -167.55M |
| March 31, 2014 | -140.88M |
| December 31, 2013 | -123.69M |
Free Cash Flow Range, Past 5 Years
-272.60M
Minimum
Mar 2021
-18.44M
Maximum
Mar 2024
-188.91M
Average
-213.14M
Median
Free Cash Flow Benchmarks
| Zoetis Inc | 1.75B |
| Corcept Therapeutics Inc | 124.84M |
| Nektar Therapeutics | -189.17M |
| Stereotaxis Inc | -8.683M |
| Cara Therapeutics Inc | -91.12M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -1.022M |
| Cash from Investing (Quarterly) | 17.03M |
| Cash from Financing (Quarterly) | -1.716M |
| Free Cash Flow Per Share (Quarterly) | -0.0231 |
| Free Cash Flow to Equity (Quarterly) | -1.113M |
| Free Cash Flow to Firm (Quarterly) | -1.113M |
| Free Cash Flow Yield | -4.21% |